journal article·2019-12-06Open access

Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin

Aneta Cymbaluk-Płoska, Peter Sobolewski, Anita Chudecka-Głaz, Ewa Wiśniewska, Joanna Łapczuk, Marcin Frankowski, Marek Droździk, Miroslawa El Fray

Abstract

Despite on-going medical advances, ovarian cancer survival rates have stagnated. In order to improve IP delivery of platinum-based antineoplastics, we aimed to develop a sustained drug delivery system for carboplatin (CPt). Toward this aim, we pursued a double emulsion process for obtaining CPt-loaded microcapsules composed of poly(ethylene terephthalate-ethylene dilinoleate) (PET-DLA) copolymer. We were able to obtain PET-DLA microspheres in the targeted size range of 10–25 µm (median: 18.5 µm), to reduce intraperitoneal clearance by phagocytosis and lymphoid transit. Empty microspheres showed the lack of toxicity in vitro. The double emulsion process yielded 2.5% w/w CPt loading and obtained microcapsules exhibited sustained (>20 day) zero-order release. The encapsulated CPt was confirmed to be bioavailable, as the microcapsules demonstrated efficacy against human ovarian adenocarcinoma (SK-OV-3) cells in vitro. Following intraperitoneal injection in mice, we did not observe adhesions, only mild, clinically-insignificant, local inflammatory response. Tissue platinum levels, monitored over 14 days using atomic absorption spectroscopy, revealed low burst and reduced systemic uptake (plasma, kidney), as compared to neat carboplatin injection. Overall, the results demonstrate the potential of the developed microencapsulation system for long-term intraperitoneal sustained release of carboplatin for the treatment of ovarian cancer.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Intraperitoneal and Appendiceal Malignancies · Hemostasis and retained surgical items

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department and Clinic of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, ul. Powstanców Wlkp. 72, 70-111 Szczecin, Poland

Department of Polymer and Biomaterials Science, Faculty of Chemical Technology and Engineering, West Pomeranian University of Technology, Szczecin, Al. Piastów 45, 70-311 Szczecin, Poland

Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, ul. Powstanców Wlkp. 72, 70-111 Szczecin, Poland

Faculty of Chemistry, Adam Mickiewicz University in Poznań, ul. Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland

Funding

Narodowe Centrum Nauki

References (49)

Show source-provided references
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries10.3322/caac.21492 ↗
2. (2019, October 04). The World Ovarian Cancer Coalition Atlas: Global Trends in Incidence, Mortality and Survival. Available online: https://www.semanticscholar.org/paper/THE-WORLD-OVARIAN-CANCER-COALITION-ATLAS-GLOBAL-IN/67b106416bcb66f605debf039b56ff37a530a288#citing-papers.
3. Ovarian cancer relapse: From the latest scientific evidence to the best practice10.1016/j.critrevonc.2019.05.014 ↗
4. First-line treatment of advanced ovarian cancer: Current research and perspectives10.1586/era.09.167 ↗
5. Jaaback, K., Johnson, N., and Lawrie, T.A. (2011). Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst. Rev.10.1002/14651858.CD005340.pub3 ↗
6. Pharmacokinetics of carboplatin after intraperitoneal administration10.1007/BF00262740 ↗
7. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. i10.1016/j.ygyno.2005.06.055 ↗
8. Raavé, R., de Vries, R.B.M., Massuger, L.F., van Kuppevelt, T.H., and Daamen, W.F. (2015). Drug delivery systems for ovarian cancer treatment: A systematic review and meta-analysis of animal studies. PeerJ, 3.10.7717/peerj.1489 ↗
9. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles10.1038/ncomms2282 ↗
10. Analysis of nanoparticle delivery to tumours10.1038/natrevmats.2016.14 ↗
11. Tabata, Y., and Ikada, Y. (2005). Phagocytosis of polymer microspheres by macrophages. New Polymer Materials, Springer.
12. Biodegradation and biocompatibility of PLA and PLGA microspheres10.1016/S0169-409X(97)00048-3 ↗
13. Microencapsulation by solvent evaporation: State of the art for process engineering approaches10.1016/j.ijpharm.2008.07.018 ↗
14. Biodegradable cisplatin microspheres prepared by the solvent evaporation method: Morphology and release characteristics10.1016/0168-3659(88)90054-5 ↗
15. Polymer-coated albumin microspheres as carriers for intravascular tumour targeting of cisplatin10.1007/BF00687320 ↗
16. Carboplatin Sustained Delivery System Using Injectable Microspheres10.1111/j.1439-0442.2005.00751.x ↗
17. Reduction of systemic exposure and toxicity of cisplatin by encapsulation in poly-lactide-co-glycolide
18. Controlled cisplatin delivery system using poly (d, l-lactic acid]10.1016/0142-9612(92)90189-U ↗
19. Pharmacologic effects of cisplatin microspheres on peritoneal carcinomatosis in rodents10.1002/1097-0142(19930201)71:3<844::AID-CNCR2820710330>3.0.CO;2-H ↗
20. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer
21. Design and testing of a new cisplatin form using a base material by combining poly-D,L-lactic acid and polyethylene glycol acid against peritoneal metastasis10.1002/(SICI)1097-0215(19980529)76:5<709::AID-IJC16>3.0.CO;2-Z ↗
22. Carboplatin -loaded PLGA microspheres for intracerebral injection: Formulation and characterization10.1080/026520499288753 ↗
23. Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres10.1016/S0939-6411(02)00037-1 ↗
24. Cisplatin incorporated in microspheres: Development and fundamental studies for its clinical application10.1016/S0168-3659(03)00131-7 ↗
25. Lung-targeting microspheres of carboplatin10.1016/S0378-5173(03)00332-6 ↗
26. A novel drug delivery system of intraperitoneal chemotherapy for peritoneal carcinomatosis using gelatin microspheres incorporating cisplatin10.1016/j.surg.2013.04.054 ↗
27. Fan, L., and Singh, S.K. (1989). Diffusion-Controlled Release. Controlled Release A Quantitative Treatment, Springer.10.1007/978-3-642-74507-2 ↗
28. Chudecka-Głaz, A., Szczeblińska, J., Cymbaluk-Płoska, A., Kohn, J., and El Fray, M. (2016). New poly (ester-amide) copolymers modified with polyether (PEAE) for anticancer drug encapsulation. J. Microencapsul., 33.10.1080/02652048.2016.1228708 ↗
29. Poly (ethylene terephthalate) modification with the monomer from renewable resources10.14314/polimery.2007.885 ↗
30. Influence of TiO 2 Nanoparticles Incorporated into Elastomeric Polyesters on their Biocompatibility In Vitro and In Vivo
31. Nanocomposite Elastomeric Biomaterials for Myocardial Tissue Engineering Using Embryonic Stem Cell-derived Cardiomyocytes10.1002/adem.201080078 ↗
32. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum10.1002/jbm.a.30654 ↗
33. Particle control of emulsion by membrane emulsification and its applications10.1016/S0169-409X(00)00099-5 ↗
34. Microfluidic approach for encapsulation via double emulsions10.1016/j.coph.2014.08.003 ↗
35. ISO (2009). Biological Evaluation of Medical Devices—Part 5: Tests for in Vitro Cytotoxicity, ISO.
36. (2019, October 04). DrugBank Carboplatin. Available online: http://www.drugbank.ca/drugs/DB00958.
37. Pénzváltó, Z., Lánczky, A., Lénárt, J., Meggyesházi, N., Krenács, T., Szoboszlai, N., Denkert, C., Pete, I., and Győrffy, B. (2014). MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer. BMC Cancer, 14.10.1186/1471-2407-14-837 ↗
38. Helland, Ø., Popa, M., Bischof, K., Gjertsen, B.T., McCormack, E., and Bjørge, L. (2016). The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. PLoS ONE, 11.10.1371/journal.pone.0158208 ↗
39. Pathophysiology and prevention of postoperative peritoneal adhesions10.3748/wjg.v17.i41.4545 ↗
40. Influence of thermally exfoliated graphite on physicochemical, thermal and mechanical properties of copolyester nanocomposites10.14314/polimery.2016.482 ↗
41. The effect of carbon nanoparticles on biological properties of polyester nanocomposites10.1177/0885328217706193 ↗
42. The effects of nano-sized carbon fillers on the physico-chemical, mechanical, and biological properties of polyester nanocomposites10.1016/j.eurpolymj.2018.08.012 ↗
43. Fiji: An open-source platform for biological-image analysis10.1038/nmeth.2019 ↗
44. Nonphospholipid Vesicles of Carboplatin for Lung Targeting10.1080/713840364 ↗
45. Sittampalam, G., and Coussens, N. (2004). Cell Viability Assays. Assay Guidance Manual, Eli Lilly & Company and the National Center for Advancing Translational Sciences.
46. Analysis of FDA-Approved Anti-Cancer Agents in the NCI60 Panel of Human Tumor Cell Lines10.1158/1535-7163.MCT-10-0106 ↗
47. Ritz, C., Baty, F., Streibig, J.C., and Gerhard, D. (2015). Dose-Response Analysis Using R. PLoS ONE, 10.10.1371/journal.pone.0146021 ↗
48. Gynecologic Oncology Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model10.1016/j.ygyno.2009.08.028 ↗
49. Prevention of Carboplatin-induced Resistance in Human Ovarian Tumor Xenografts by Selenite